Underestimated Input of a Central Lab During the Clinical Trial Planning Phase
Sponsored by: Synevo Central Labs
- Clinical Trials
- Clinical Trial Planning
- Central Lab Services
Date: 18 October
Time: 3PM London/10AM New York
Clinical trials are growing in complexity, particularly with regards to laboratories.
There is a tendency to include unnecessary protocols and inappropriate laboratory procedures in studies that can lead to complicated study sample logistics and large courier costs as a result.
Early engagement of a central lab during a clinical trial planning phase can save a lot of money and time for the study sponsor as well as a lot of unnecessary stress to the project management and investigator teams. We would like to share with you few real life cases that we have experienced in the last couple of years.
We will present the consequences of the protocol's initial assumptions, our proposed solutions and the achieved results. In such a competitive market as Pharmaceuticals, drug developers cannot afford to waste money and must utilize expertise and experience of all clinical trials parties, especially central laboratories, at the earliest possible stage of a clinical trial.
Tomasz Anyszek, MD, PhD, EuSpLM,
Synevo Central Labs Director
Tomasz Anyszek has been the Director of Synevo Central Lab since 2009 and is responsible for clinical trials operations in more than 50 laboratories in Central and Eastern Europe.
Dr. Anyszek started his career with Virtual Central Laboratory, Netherlands in 2000 (Covance VCL since 2003) and his experience also includes the coordination of 16 regional Covance partner laboratories in Europe. During this period he performed about 200 audits in clinical laboratories.
Dr. Anyszek holds his PhD from Jagiellonian University, Poland. Prior to his business career, he taught clinical biochemistry and laboratory medicine at the Jagiellonian University medical faculty. Dr. Anyszek has authored more than 20 scientific publications and co-authored several books and monographies in the clinical chemistry and laboratory medicine area.
Michal Dysko, MBA,
Head of Business Development
Michal Dysko has more than 13 years of experience in the clinical research industry from the clinical trial services provider perspective. Michal is Head of Business Development at Synevo Central Labs, the largest wholly-owned, GCLP accredited and fully-harmonized network of central laboratories in Europe dedicated exclusively to support clinical trials. Michal has joined Synevo Central Labs in 2008 and is responsible for sales and marketing operations of the whole network.
Before joining Synevo Central Labs, he has been Sales and Marketing Director at Kiecana Clinical Research, the Central and Eastern European CRO headquartered in Poland, since 2003. In 2005, he has joined Europharm Research, UK based CRO, as Executive Director, Business Development.
Since 2006 to 2008 he has been Managing Director at privately-held consulting company in the clinical research field. Michal has obtained his MBA degree from the University of Quebec at Montreal and the Warsaw School of Economics in 2003.
Key Learning Objectives
- The central lab role in clinical trials
- Key challenges of the industry
- Communication between parties of a clinical project
- Benefits of a central lab input during a clinical study planning phase
- Clinical Operations Directors
- Heads of Clinical Development
- Heads of Clinical Research
- Clinical Outsourcing Managers
- Heads of Outsourcing and Vendor Management
- Clinical Trial Managers
- Clinical Study Managers